This content is from: Patents
Federal Circuit vacates injunction in Amgen’s dispute with Sanofi
The permanent injunction granted by the District of Delaware in the dispute between Amgen and Sanofi/Regeneron over cholesterol-lowering treatment has been vacated, in a decision that also included some implications for the USPTO’s practice of granting broad antibody claims
Get Free Access to read more …
To read the full article, activate your free trial.
Get Free Access- Unlimited articles for one week
- No commitments; no payment details required
- Featuring IP strategy, copyright, patents, trademark and more!
Are you a Managing IP subscriber? Simply login here.